The corporate social responsibility of pharmaceutical product recalls: An empirical examination of U.s. And U.k. Markets [Book Review]
David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Journal of Business Ethics 76 (4):427 - 449 (2007)
The pressure on companies to practice corporate social responsibility (CSR) has gained momentum in recent times as a means of sustaining competitive advantage in business. The pharmaceutical industry has been acutely affected by this trend. While pharmaceutical product recalls have become rampant and increased dramatically in recent years, no comprehensive study has been conducted to study the effects of announcements of recalls on the shareholder returns of pharmaceutical companies. As product recalls could significantly damage a company's reputation, profitability and brand integrity, this paper investigates the effect on shareholder wealth and the extent to which the adoption of CSR practices by pharmaceutical companies in the United Kingdom (U.K.) and the United States (U.S.), the two largest markets for pharmaceutical products in the world, affected market reactions surrounding product recall announcements. The analysis of product recall announcements from 1998 to 2004 compiled from The Pharmaceutical Journal and U.S. Food and Drug Administration enforcement reports revealed marked differences in the way market participants in the two countries responded to news of product recalls. U.S. investors penalised firms according to the severity of product defects while U.K. investors were indifferent. While U.K. investors rewarded product recalls by firms which were not usually CSR-active, U.S. investors punished non-CSR active firms that performed recalls. These observations could pose strategic challenges to pharmaceutical firms operating in both countries
|Keywords||corporate social responsibility pharmaceutical industry product recalls shareholder wealth UK and US comparison|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
Pepijn K. C. van de Pol & Frank G. A. de Bakker (2010). Direct-to-Consumer Advertising of Pharmaceuticals as a Matter of Corporate Social Responsibility? Journal of Business Ethics 94 (2):211-224.
Olga Bruyaka, Hanko K. Zeitzmann, Isabelle Chalamon, Richard E. Wokutch & Pooja Thakur (2013). Strategic Corporate Social Responsibility and Orphan Drug Development: Insights From the US and the EU Biopharmaceutical Industry. [REVIEW] Journal of Business Ethics 117 (1):45-65.
Pieter Jong, Antony Paulraj & Constantin Blome (2014). The Financial Impact of ISO 14001 Certification: Top-Line, Bottom-Line, or Both? Journal of Business Ethics 119 (1):131-149.
Pepijn K. C. Van de Pol & Frank G. A. De Bakker (2010). Direct-to-Consumer Advertising of Pharmaceuticals as a Matter of Corporate Social Responsibility? Journal of Business Ethics 94 (2):211 - 224.
Similar books and articles
Wenjing Li & Ran Zhang (2010). Corporate Social Responsibility, Ownership Structure, and Political Interference: Evidence From China. [REVIEW] Journal of Business Ethics 96 (4):631 - 645.
Chieh-Peng Lin, Shwu-Chuan Chen, Chou-Kang Chiu & Wan-Yu Lee (2011). Understanding Purchase Intention During Product-Harm Crises: Moderating Effects of Perceived Corporate Ability and Corporate Social Responsibility. [REVIEW] Journal of Business Ethics 102 (3):455-471.
Guido Berens, Cees B. M. van Riel & Johan van Rekom (2007). The CSR-Quality Trade-Off: When Can Corporate Social Responsibility and Corporate Ability Compensate Each Other? [REVIEW] Journal of Business Ethics 74 (3):233 - 252.
Linda O'Riordan & Jenny Fairbrass (2008). Corporate Social Responsibility (CSR): Models and Theories in Stakeholder Dialogue. [REVIEW] Journal of Business Ethics 83 (4):745 - 758.
Linda O’Riordan & Jenny Fairbrass (2008). Corporate Social Responsibility (Csr): Models and Theories in Stakeholder Dialogue. [REVIEW] Journal of Business Ethics 83 (4):745 - 758.
Morgan P. Miles, Linda S. Munilla & Jeffrey G. Covin (2002). The Constant Gardener Revisited: The Effect Ofsocial Blackmail on the Marketing Concept,Innovation, and Entrepreneurship. [REVIEW] Journal of Business Ethics 41 (3):287 - 295.
Yan Leung Cheung, Weiqiang Tan, Hee-Joon Ahn & Zheng Zhang (2010). Does Corporate Social Responsibility Matter in Asian Emerging Markets? Journal of Business Ethics 92 (3):401 - 413.
Matthew Lee & Jillian Kohler (2010). Benchmarking and Transparency: Incentives for the Pharmaceutical Industry's Corporate Social Responsibility. [REVIEW] Journal of Business Ethics 95 (4):641-658.
Ashish Chandra & Gary A. Holt (1999). Pharmaceutical Advertisements: How They Deceive Patients. [REVIEW] Journal of Business Ethics 18 (4):359 - 366.
Pepe Lee Chang (2006). Who's in the Business of Saving Lives? Journal of Medicine and Philosophy 31 (5):465 – 482.
Added to index2009-01-28
Total downloads14 ( #119,025 of 1,100,145 )
Recent downloads (6 months)4 ( #90,386 of 1,100,145 )
How can I increase my downloads?